OPKO Health, Inc. will report Q3 2026 results on November 4, 2026, with a conference call at 4:30 p.m. ET.
Quiver AI Summary
OPKO Health, Inc. announced that it will release its financial and operational results for the third quarter of 2026 on November 4, 2026. Following the release, OPKO's senior management will conduct a conference call and webcast at 4:30 p.m. ET to provide insights into the business, discuss the results, and offer financial guidance. Participants are encouraged to pre-register for the call to receive immediate access, although they can also join by dialing in directly. A replay of the call will be available for a limited time, and further information about OPKO and its offerings can be found on their website.
Potential Positives
- Announcement of third quarter 2026 operating and financial results highlights OPKO's commitment to transparency and communication with stakeholders.
- Scheduled conference call and webcast provide an opportunity for real-time engagement with management, allowing investors to gain insights directly from company leaders.
- Inclusion of advanced biopharmaceutical technologies in OPKO's research and development indicates a strong focus on innovation and potential future growth in serious disease treatment.
Potential Negatives
- None
FAQ
When will OPKO Health report its third-quarter 2026 results?
OPKO Health will report its third-quarter 2026 results on Wednesday, November 4, 2026.
How can I access the OPKO Health conference call?
You can access the conference call by pre-registering for a unique PIN or by calling 833-630-0584 (U.S.) or 412-317-1815 (International).
Is there a webcast available for the OPKO results presentation?
Yes, a webcast of the conference call will be available through OPKO’s Investor Relations.
What is the duration of the telephone replay for the conference call?
The telephone replay will be available until November 11, 2026.
What areas does OPKO Health focus on in its research?
OPKO Health focuses on developing therapeutics for serious diseases, including multispecific antibody technologies and CAR-T therapies.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OPK Hedge Fund Activity
We have seen 90 institutional investors add shares of $OPK stock to their portfolio, and 77 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 3,596,980 shares (+inf%) to their portfolio in Q2 2026, for an estimated $5,395,470
- HIGHBRIDGE CAPITAL MANAGEMENT LLC added 3,593,925 shares (+inf%) to their portfolio in Q2 2026, for an estimated $5,390,887
- UBS GROUP AG removed 1,065,148 shares (-17.5%) from their portfolio in Q2 2026, for an estimated $1,597,722
- JANE STREET GROUP, LLC removed 884,921 shares (-79.4%) from their portfolio in Q2 2026, for an estimated $1,327,381
- TEJARA CAPITAL LTD removed 877,941 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $1,316,911
- MORGAN STANLEY added 778,940 shares (+65.1%) to their portfolio in Q2 2026, for an estimated $1,168,410
- BLACKROCK, INC. added 746,670 shares (+2.1%) to their portfolio in Q2 2026, for an estimated $1,120,005
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a multinational biopharmaceutical company, today announced that it will report operating and financial results for the third quarter 2026 on Wednesday, November 4, 2026. OPKO’s senior management will host a conference call and webcast at 4:30 p.m. ET to provide a business update, discuss results and financial guidance.
CONFERENCE CALL & WEBCAST INFORMATION
OPKO encourages participants to pre-register for the conference call using this link . Participants who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participants may register at any time, including up to and after the call start time. Those unable to pre-register may participate by dialing 833-630-0584 (U.S.) or 412-317-1815 (International). A webcast of the call can also be accessed through OPKO’s Investor Relations here .
A telephone replay will be available until November 11, 2026, by dialing 855-669-9658 (U.S.) or 412-317-0088 (International) and providing the passcode 3222736. A webcast replay will be available beginning approximately one hour after the completion of the live conference call through OPKO’s Investor Relations here .
About OPKO Health
OPKO Health, Inc. is a multinational biopharmaceutical company focused on developing and delivering therapeutics for serious diseases across global markets. The company’s research and development programs include multispecific antibody technologies, in vivo CAR-T delivered through antibody-guided lipid nanoparticles, and proprietary long-acting peptide and protein engineering capabilities. OPKO also operates specialty pharmaceutical businesses across several international markets.
For more information, visit www.opko.com .
Contacts:
Alliance Advisors IR
Vivian Cervantes, 973-873-7724
[email protected]
